search
Back to results

Study of HuCNS-SC Cells in Patients With Infantile or Late Infantile Neuronal Ceroid Lipofuscinosis (NCL)

Primary Purpose

Neuronal Ceroid Lipofuscinosis

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Surgery to implant human CNS stem cells (HuCNS-SC)
Medication to suppress the immune system
Sponsored by
StemCells, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Neuronal Ceroid Lipofuscinosis focused on measuring NCL, INCL, LINCL, Batten disease, Infantile Neuronal Ceroid Lipofuscinosis (INCL), Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL)

Eligibility Criteria

18 Months - 12 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patients MAY be eligible to participate in this research study if they: Are age 18 months to 12 years old Have a clinical diagnosis of infantile neuronal ceroid lipofuscinosis (INCL) or late infantile neuronal ceroid lipofuscinosis (LINCL) Have a mutation of the CLN1 or CLN2 gene Have severe cognitive, communication, behavior and language impairment Exclusion Criteria: Patients may not be eligible to participate in this research study if they: Have cognitive, communication, behavior and language function less than that of a 1 year old Have previously received an organ, tissue or bone marrow transplantation Have previously participated in any gene or cell therapy study Have infection with hepatitis virus, Cytomegalovirus, Epstein Barr Virus, or Human Immunodeficiency Virus (HIV) Have a current or prior cancer Have a bleeding disorder Are unable to have an MRI scan

Sites / Locations

  • Oregon Health and Science University

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

HuCNS-SC

Arm Description

human central nervous system stem cells

Outcomes

Primary Outcome Measures

Safety

Secondary Outcome Measures

Preliminary efficacy

Full Information

First Posted
June 13, 2006
Last Updated
January 13, 2015
Sponsor
StemCells, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT00337636
Brief Title
Study of HuCNS-SC Cells in Patients With Infantile or Late Infantile Neuronal Ceroid Lipofuscinosis (NCL)
Official Title
A Phase I Study of the Safety and Preliminary Effectiveness of Human CNS Stem Cells (HuCNS-SC) in Patients With Neuronal Ceroid Lipofuscinosis Caused by Palmitoyl Protein Thioesterase 1 (PPT1) or Tripeptidyl Peptidase 1 (TPP-I) Deficiency
Study Type
Interventional

2. Study Status

Record Verification Date
January 2015
Overall Recruitment Status
Completed
Study Start Date
May 2006 (undefined)
Primary Completion Date
February 2009 (Actual)
Study Completion Date
September 2009 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
StemCells, Inc.

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Patients with infantile or late infantile NCL have either a reduced amount of, or are missing, the palmitoyl protein thioesterase 1 (PPT1) enzyme or the tripeptidyl peptidase 1 (TPP-I) enzyme. Human central nervous system stem cells (HuCNS-SC) are an investigational product derived from human brain cells. HuCNS-SC have been shown to survive and migrate within the brains of mice. When grown in the laboratory, HuCNS-SC have been shown to produce the PPT1 and TPP-I enzymes. In mice missing the PPT1 enzyme, HuCNS-SC have been shown to increase the amount of this enzyme in the brain, to reduce the amount of abnormal storage material in the brain, and to prevent the death of some neurons (a type of cell) in the brain. Participation in this study will involve screening assessments, surgery to implant HuCNS-SC, medication to suppress the immune system, and a series of follow-up assessments. The length of time from the start of screening through to the last follow-up visit will be approximately 13 months, with frequent visits to the study center during this time. After completion of this study, patients will be monitored for an additional 4 years under a separate long term follow-up protocol.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Neuronal Ceroid Lipofuscinosis
Keywords
NCL, INCL, LINCL, Batten disease, Infantile Neuronal Ceroid Lipofuscinosis (INCL), Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL)

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
6 (Actual)

8. Arms, Groups, and Interventions

Arm Title
HuCNS-SC
Arm Type
Experimental
Arm Description
human central nervous system stem cells
Intervention Type
Procedure
Intervention Name(s)
Surgery to implant human CNS stem cells (HuCNS-SC)
Other Intervention Name(s)
HuCNS-SC
Intervention Description
single dose
Intervention Type
Drug
Intervention Name(s)
Medication to suppress the immune system
Intervention Description
Immunosuppression for 12 months post transplant
Primary Outcome Measure Information:
Title
Safety
Time Frame
one year post transpant
Secondary Outcome Measure Information:
Title
Preliminary efficacy
Time Frame
one year post transplant

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Months
Maximum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients MAY be eligible to participate in this research study if they: Are age 18 months to 12 years old Have a clinical diagnosis of infantile neuronal ceroid lipofuscinosis (INCL) or late infantile neuronal ceroid lipofuscinosis (LINCL) Have a mutation of the CLN1 or CLN2 gene Have severe cognitive, communication, behavior and language impairment Exclusion Criteria: Patients may not be eligible to participate in this research study if they: Have cognitive, communication, behavior and language function less than that of a 1 year old Have previously received an organ, tissue or bone marrow transplantation Have previously participated in any gene or cell therapy study Have infection with hepatitis virus, Cytomegalovirus, Epstein Barr Virus, or Human Immunodeficiency Virus (HIV) Have a current or prior cancer Have a bleeding disorder Are unable to have an MRI scan
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Robert Steiner, MD
Organizational Affiliation
Oregon Health and Science University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Oregon Health and Science University
City
Portland
State/Province
Oregon
ZIP/Postal Code
97239
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
23581634
Citation
Selden NR, Al-Uzri A, Huhn SL, Koch TK, Sikora DM, Nguyen-Driver MD, Guillaume DJ, Koh JL, Gultekin SH, Anderson JC, Vogel H, Sutcliffe TL, Jacobs Y, Steiner RD. Central nervous system stem cell transplantation for children with neuronal ceroid lipofuscinosis. J Neurosurg Pediatr. 2013 Jun;11(6):643-52. doi: 10.3171/2013.3.PEDS12397. Epub 2013 Apr 12.
Results Reference
derived

Learn more about this trial

Study of HuCNS-SC Cells in Patients With Infantile or Late Infantile Neuronal Ceroid Lipofuscinosis (NCL)

We'll reach out to this number within 24 hrs